37 participants
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2025-09-23
- Start Date:
- 2024-10-10
- Completion:
- 2029-03-30
Conditions
- Salivary Gland Neoplasm Duct
Interventions
- DRUG
No Results Yet